

1 **SACHRP Charge**

2 **Interpretation of Public Health Authority and Public Health Surveillance Activities,**  
3 **46.102(k), 46.102(l)(2)**

4  
5 **Introduction**

6 OHRP is frequently asked to respond to questions from the research community regarding the  
7 interpretation and application of 45 CFR 46.102(k) and (l)(2). While OHRP and other HHS  
8 agencies have already considered these questions, OHRP asks SACHRP to independently  
9 deliberate the questions below and come to its own objective recommendations. OHRP would be  
10 interested in SACHRP's views even if additional rulemaking were necessary to clarify or modify  
11 aspects of the regulations.

12 The regulatory text is as follows:

13 45 CFR 46.102(k)

14 Public health authority means an agency or authority of the United States, a state, a  
15 territory, a political subdivision of a state or territory, an Indian tribe, or a foreign  
16 government, or a person or entity acting under a grant of authority from or contract with  
17 such public agency, including the employees or agents of such public agency or its  
18 contractors or persons or entities to whom it has granted authority, that is responsible for  
19 public health matters as part of its official mandate.

20 45 CFR 46.102(l)(2)

21 Public health surveillance activities, including the collection and testing of information or  
22 biospecimens, conducted, supported, requested, ordered, required, or authorized by a  
23 public health authority. Such activities are limited to those necessary to allow a public  
24 health authority to identify, monitor, assess, or investigate potential public health signals,  
25 onsets of disease outbreaks, or conditions of public health importance (including trends,  
26 signals, risk factors, patterns in diseases, or increases in injuries from using consumer  
27 products). Such activities include those associated with providing timely situational  
28 awareness and priority setting during the course of an event or crisis that threatens public  
29 health (including natural or man-made disasters).

30 In the pre-2018 version of the Common Rule, there were a number of categories of exempt  
31 research, which were presented at 45 CFR 46.101(b)(1) through (b)(6). Of note, these are human  
32 subjects research, but research that is exempt from the requirements of the Common Rule. In the  
33 revised Common Rule, known as the 2018 Requirements, those exemptions were modified  
34 extensively and were moved to 45 CFR 46.104. In addition, the definition of research was  
35 modified at 45 CFR 46.102(l) to include four activities which "are deemed not to be research."  
36 These four activities are commonly referred to as "exclusions," although that term was not  
37 carried over from the NPRM and the Federal Register announcement (Vol. 82, No. 12 /Thursday,  
38 January 19, 2017, page 7149) into the 2018 Requirements. There is some conceptual confusion as

**Commented [DF1]:** The NPRM and the draft OHRP guidance use the term "exclusion." The questions to SACHRP used the term "exemption." To better tie this recommendation to the NPRM legislative history and the draft guidance, the term "exclusion" is used throughout this document, including in the questions themselves.

to whether the four exclusions are not research or alternatively are research that does not require compliance with the 2018 Requirements, similar to the exemptions at 45 CFR 46.104, but in the end that distinction does not have practical implications and does not need to be resolved in order to apply the exclusions.

#### SACHRP Opening Comments

The Common Rule serves two distinct purposes. First, it articulates application of broad ethical principles and sets expectations about how we should treat one another. This purpose is what we usually debate, e.g., how to balance the needs of society and the individual where the regulations are not directive. But it is also a practical tool to further social utility. It provides an expectation of what the research enterprise must do to maintain public trust to further the social goal of scientific progress. The purposes of the FDA regulations are different: their social utility is not broad scientific progress, but sustaining trust to allow the collection of data to ensure that medical practices are safe and effective.

**Commented [DF2]:** Not sure this sentence is worth keeping

Seen from this perspective, the exclusion to the Common Rule for Public Health Surveillance Activities (PHSAs) is more than a simple technical exclusion. Instead, it is a recognition that the goal of PHSAs is not to support scientific progress, but rather to support the more immediate goal of maintaining public health. Indirectly, scientific progress may ultimately support public health, but only in a general way the details of which cannot be predicted. In the same way that a particular activity can be either research or quality improvement depending on its purpose, a particular activity can be either research or a public health surveillance activity.

Confusion with the wording of the regulations arises because we are committed to scientific progress as a way to improve population health. Thus, descriptions of public health surveillance activities as “activities... to allow a public health authority to identify, monitor, assess or investigate... conditions of public health importance” could be broadly applied to almost any clinical research conducted by the National Institutes of Health. However, to do so confuses direct support of maintaining public health with our aspirational expectations for scientific progress.

Therefore, SACHRP believes that just because an agency is designated as a public health agency, that does not mean that every activity conducted by the agency is a public health activity, or a public health surveillance activity, or that every department in the agency is conducting public health activities. For instance, NIH performs some public health activities, but much of the work NIH does is not a public health activity.

Finally, SACHRP notes that if a proposed activity does not meet the exclusion provided by 45 CFR 46.102(l)(2), and it meets the definition of research, then the practical effect is that IRB review will be required unless the activity meets one of the exemptions under 45 CFR 46.104. In many cases, if the activity is research, it will be minimal risk (if it has appropriate protections for confidentiality) and may also qualify for a waiver of consent under 45 CFR 46.116(f).

79

80 **SACHRP Responses**

81 **OHRP Question 1.** What entities should be considered to meet the Common Rule definition  
82 of a ‘public health authority’? Note that this definition is largely the same as the HIPAA  
83 definition, so please consider past applications of this definition in the HIPAA context as well.

84 (a) If a Federal agency that is a public health authority engages in a partnership with a private  
85 institution to conduct public health surveillance activities, should (or might) the institution be  
86 considered to be a ‘public health authority’ in this context? Please consider providing an  
87 explanation as to why or why not the institution should (or might) be considered to be a “public  
88 health authority.”

89 The HIPAA definition is below for convenience.

90 45 CFR 164.501

91 Public health authority means an agency or authority of the United States, a State, a  
92 territory, a political subdivision of a State or territory, or an Indian tribe, or a person or  
93 entity acting under a grant of authority from or contract with such public agency,  
94 including the employees or agents of such public agency or its contractors or persons or  
95 entities to whom it has granted authority, that is responsible for public health matters as  
96 part of its official mandate.

97 **SACHRP answer to Question 1**

98 SACHRP supports the harmonization of definitions across HHS, FDA and OCR, as evidenced  
99 by the creation of the standing SACHRP Subcommittee on Harmonization. Therefore, SACHRP  
100 encourages reliance on past applications of this definition of a “public health authority” in the  
101 HIPAA context.

102 The Committee does note one significant difference between the definitions; the Common Rule  
103 definition includes an agency or authority of “a foreign government” as well as US agencies and  
104 authorities, whereas the HIPAA definition is limited to US agencies and authorities. SACHRP  
105 believes that the extension of this exclusion to a foreign government should be interpreted as  
106 narrowly as possible, with the only use being the use of US federal funds to conduct public  
107 health surveillance activities in the foreign government’s country only. It should not be used to  
108 allow a foreign government to conduct public health surveillance activities in the United States  
109 or in a country other than that of the foreign government.

110 The definition appears to be quite broad. A plain reading of the regulation indicates that a person  
111 or entity acting under a grant of authority from, or contract with, such public agency is also a  
112 public health authority. Therefore, institutions or private companies could meet the definition.

113 **SACHRP answer to Question 1(a)**

114 If a Federal agency that is a public health authority engages in a partnership with a private  
115 institution to conduct public health surveillance activities, the private institution should not be

116 considered to be a ‘public health authority’ solely based on the partnership. The plain reading of  
117 the definition is that a public health authority must be an agency or authority of the US or a  
118 foreign government. A private institution does not meet that definition per se. However, if the  
119 partnership involves a “grant of authority from or contract with such public agency,” then the  
120 private institution is a public health authority by the definition.

121 SACHRP recommends that the grant of authority be interpreted narrowly when a private  
122 institution is designated to become a public health authority. The grant of authority or contract  
123 should be clearly limited to a defined public health surveillance activity. It should not be  
124 allowed to extend to other projects or other activities and still be considered to fall under the  
125 exclusion. Furthermore, as noted in the preamble to the 2018 Requirements, “subsequent  
126 research using information collected during a public health surveillance activity, for instance,  
127 genetic analysis of biospecimens, would not be removed from the definition” of research. (FR  
128 Vol. 82, No. 12, Thursday, January 19, 2017, p. 7176.)

129  
130 Also, SACHRP notes that the preamble describes certain research activities that do not fall under  
131 the exclusion. As noted in the preamble:

132 “This clarification of current interpretation would not remove the following activities  
133 from the definition of “research”: exploratory studies designed to better understand risk  
134 factors for chronic diseases, including genetic predisposition, for chronic diseases;  
135 exploratory studies designed to elucidate the relationships between biomarkers of  
136 exposure and biomarkers of disease; and exploratory studies of potential relationships  
137 between behavioral factors (e.g., diet) and indicators of environmental exposures. These  
138 types of activities would be considered research because they would not be conducted  
139 solely for the purposes described in §\_\_.102(l)(2), and thus would be covered by the  
140 Common Rule if they involved human subjects, even if conducted by a federal agency  
141 with a public health mandate. Again, they might fall within an exemption, depending on  
142 how they are carried out.” (FR Vol. 82, No. 12, Thursday, January 19, 2017, p. 7176)

143  
144 Finally, SACHRP recommends the grant of authority should be clearly documented in a legal  
145 document, which can take several forms, such as an MOU, contract, purchase order or letter. It  
146 should clearly cite to a federal or state law or regulation. Both the Office of Civil Rights (OCR)  
147 and the Centers for Disease Control (CDC) has given examples of such grants.

148 In the preamble to the Privacy Rule, OCR said:

149 In some circumstances, a person or entity acting on behalf of a government agency may  
150 make a request for disclosure of protected health information under these subsections.  
151 For example, public health agencies may contract with a nonprofit agency to collect and  
152 analyze certain data. In such cases, the covered entity is required to verify the requestor’s  
153 identity and authority through examination of reasonable documentation that the  
154 requestor is acting on behalf of the government agency. Reasonable evidence includes a  
155 written request provided on agency letterhead that describes the legal authority for  
156 requesting the release and states that the person or entity is acting under the agency’s  
157 authority, or other documentation, including a contract, a memorandum of understanding,

or purchase order that confirms that the requestor is acting on behalf of the government agency. 65 FR 82462, 82547 (Dec. 28, 2000).

CDC has also addressed this issue in its guidance entitled “HIPAA Privacy Rule and Public Health: CDC Guidance (April 11, 2003),” which says:

Public health agencies often conduct their authorized public health activities with other entities by using different mechanisms (e.g., contracts and memoranda or letters of agreement). These other entities are public health authorities under the Privacy Rule with respect to the activities they conduct under a grant of authority from such a public health agency. A covered entity may disclose PHI to public health authorities and to these designated entities pursuant to the public health provisions of the Privacy Rule. <https://www.cdc.gov/mmwr/preview/mmwrhtml/m2e411a1.htm>.

For transparency, the grant of authority should be publicly available and easy for the public to locate, as public health surveillance activities involve issues of privacy.

**OHRP Question 2.** How should the exclusion operate when the public health surveillance activities will be wholly carried out by an entity outside of the Federal, State, or local government? Consider whether there is a distinction if the activities are carried out by a contractor (in which activities are directed by the awarding governmental agency through the terms of the contract, and will provide data back to the awarding agency) versus a grantee (in which activities are proposed by the grantee and are not directed by the awarding governmental agency, and which may or may not result in data being provided back to the awarding agency) versus through a public-private partnership that does not involve an award of funds. Please specifically consider the following language of the exclusion in these contexts: “The activity must be limited to that necessary to allow a public health authority to identify, monitor, assess, or investigate potential public health signals, onsets of disease outbreaks, or conditions of public health importance...” (emphasis added).

#### **SACHRP answer to Question 2**

First, we note that a plain reading of the regulation is that the definition of a public health authority includes “a person or entity acting under a grant of authority from or contract with such public agency.” Therefore, it appears that a person or private entity becomes a public health authority when such a grant of authority or contract is in place. Therefore, one might argue that a government agency or authority can designate a person or private entity to perform all of the functions of the agency or authority, even if that person or private entity does not provide the information back to the agency, because the person or private entity becomes a public health authority. However, SACHRP recommends that this provision be interpreted narrowly, and that sufficient data should be provided back to the public health agency or authority so that the agency or authority itself can “identify, monitor, assess, or investigate potential public health signals, onsets of disease outbreaks, or conditions of public health importance...” Such sufficient data may include raw data, or it may include reports or summaries.

196 Question 2 also asks whether there should be distinctions when activities are carried out by a  
197 contractor versus a grantee versus a public-private partnership that does not involve an award of  
198 funds. SACHRP recommends that this provision be interpreted narrowly, and we do not believe  
199 there should be distinctions between these arrangements, and that under each of these  
200 arrangements sufficient data should be provided back to public health agency or authority to  
201 allow the public health agency or authority to “identify, monitor, assess, or investigate potential  
202 public health signals, onsets of disease outbreaks, or conditions of public health importance...”

203 **OHRP Question 3.** What types of activities should be considered to be “public health  
204 surveillance activities” for purposes of this exclusion? Note that this term is used in the  
205 Common Rule but is not defined in the Common Rule. Please consider developing a rubric for  
206 analyzing planned activities, including specific rationale as to why certain types of activities  
207 should or should not be considered to be “public health surveillance.” For example, should the  
208 purpose of the surveillance activity be solely to inform the decisions or actions that must be  
209 made by a public health authority, or to apply study findings to public health practice? Should  
210 activities that do not meet this exclusion include disseminating findings to stimulate public  
211 health action by others, but not informing the public health authority of actions that it would take  
212 to improve public health?

213 (a) Please also consider developing illustrative case studies that describe the creation of a  
214 repository as the primary study, as well as a repository embedded within a trial. For example,  
215 consider whether establishment of a repository containing individually identifiable private  
216 information or individually identifiable biospecimens could fall within this exclusion, and what  
217 other facts would need to be known in order to address this question. For example, is it relevant  
218 if the planned uses of the repository information:

- 219
- 220 • Are unknown?
  - 221 • Would only constitute non-exempt human subjects research?
  - 222 • Would only constitute public surveillance activities that would also meet the  
223 conditions of the exclusion?
  - 224 • Would require an additional assessment to determine whether they met all the  
225 conditions of the exclusion?

### 225 **SACHRP answer to Question 3**

226 Both the exclusion itself and the preamble include activities that should be considered “public  
227 health surveillance activities.” The exclusion says that such activities are:

228

- 229
- 230 • Those necessary to allow a public health authority to identify, monitor, assess, or  
231 investigate potential public health signals, onsets of disease outbreaks, or conditions of  
232 public health importance (including trends, signals, risk factors, patterns in diseases, or  
233 increases in injuries from using consumer products); and

- Those associated with providing timely situational awareness and priority setting during the course of an event or crisis that threatens public health (including natural or man-made disasters).

The preamble says that such activities **include**:

- Collecting, analyzing, and using data to target public health and disease prevention;
- Surveillance uses data from a variety of sources, including mandatory reporting of certain conditions, routine monitoring, vital records, medical billing records, and public health investigations.
- Safety and injury surveillance activities designed to enable a public health authority to identify, monitor, assess, and investigate potential safety signals for a specific product or class of products (for example, the surveillance activities of the FDA's Adverse Event Reporting System, the Vaccine Adverse Event Reporting System, Manufacturer and User Facility Device Experience database, the Medical Product Safety Network, and the Sentinel Initiative);
- Surveillance activities designed to enable a public health authority to identify unexpected changes in the incidence or prevalence of a certain disease in a defined geographic region where specific public health concerns have been raised (*e.g.*, the U.S. influenza surveillance system...;
- Surveillance activities designed to enable a public health authority to identify the prevalence of known risk factors associated with a health problem in the context of a domestic or international public health emergency;
- Surveillance activities designed to enable a public health authority to identify the prevalence of known risk factors associated with a health problem in the context of a domestic or international public health emergency; and,
- Surveillance activities designed to enable a public health authority to detect the onset of disease outbreaks or provide timely situational awareness during the course of an event or crisis that threatens the public health, such as a natural or man-made disaster, and Surveillance activities designed to enable a public health authority to identify the prevalence of a condition of public health importance, known risk factors associated with a condition of public health importance, or behaviors or medical practices related to prevalence of a known condition of public health importance (*e.g.*, surveillance of the prevalence of: tobacco use, exposure to secondhand smoke, lung cancer, or use of smoking cessation treatments).

SACHRP does not have any suggested additions to this list. [if we do, add here]

The preamble also provides a list of research activities that do not fall under the exclusion, because they would not be conducted solely for the purposes described in §11.102(l)(2). These are:

- exploratory studies designed to better understand risk factors for chronic diseases, including genetic predisposition, for chronic diseases;
- exploratory studies designed to elucidate the relationships between biomarkers of exposure and biomarkers of disease; and

**Commented [DF3]:** Note, these are all listed in the OHRP draft guidance as well.

- exploratory studies of potential relationships between behavioral factors (*e.g.*, diet) and indicators of environmental exposures.

SACHRP does not have any suggested additions to this list. either. [if we do, add here]

#### **SACHRP answer to Question 3(a)**

Question 3(a) asks whether establishment of a repository containing individually identifiable private information or individually identifiable biospecimens could fall within this exclusion, and asks SACHRP to consider two scenarios, the creation of a repository as the primary study, as well as the creation of a repository embedded within a trial.

Regarding the creation of a repository as the primary study, SACHRP believes that if the use of the data or samples from the repository is clearly going to be for a public health surveillance activity or activities, then that use of the repository would qualify for the exclusion.

Question 3a asks whether it is relevant if the planned uses of the repository information:

- Are unknown?
- Would only constitute non-exempt human subjects research?
- Would only constitute public surveillance activities that would also meet the conditions of the exclusion?
- Would require an additional assessment to determine whether they met all the conditions of the exclusion?

SACHRP believes that the exclusion should be applied narrowly, and that in order to this exclusion to apply to the creation of a repository, there would have to be adequate description of the project to allow an application of the public health surveillance activities. If the uses were unknown, or would constitute non-exempt research, then the exclusion should not apply. If the planned uses only constitute public health surveillance activities, the exclusion should apply. As noted previously, any secondary uses of the data or samples would need to be analyzed to determine whether they meet the definition of a public health surveillance activity.

Regarding the creation of a repository embedded within a trial, and whether it might qualify for the exclusion, SACHRP notes that OHRP addressed this issue in the OHRP draft guidance “Activities Deemed Not to Be Research: Public Health Surveillance 2018 Requirements.” The draft guidance says “If an activity is composed of multiple components, some of which are not public health surveillance, OHRP’s view is that only those components that serve to enable a public health authority to carry out one or more public health surveillance objectives should be considered potentially eligible for the public health surveillance activity exclusion under 45 CFR 46.102(l)(2).”

SACHRP agrees with this position, which effectively allows public health surveillance activities that are part of a project that also has research activities to be carved out from application of the Common Rule. Therefore, if a repository is embedded in a clinical trial, and the use of the data



316 or samples from the repository is clearly going to be public health surveillance activities, then  
317 those uses of the repository qualify for the exclusion. SACHRP also notes that this is a distinct  
318 approach from the traditional approach to the issue of exempt activities that are embedded within  
319 a trial, which has been that if any part of a project qualifies as research, then the exempt parts  
320 must also receive IRB review. SACHRP recommends that this distinction is clearly highlighted  
321 in any guidance on this issue.

322 **OHRP Question 4.** The regulatory language of the exclusion provides that “[t]he activity must  
323 be conducted, supported, requested, ordered, required, or authorized by a public health  
324 authority.” What do each of these actions entail, and how do they differ? Please consider  
325 developing suggested examples illustrating each of these scenarios.

326 **SACHRP answer to Question 4**

- 327 • “Conducted” means the activity is performed by the public health authority.
- 328 • “Supported” means that the public health authority provides funding or other resources,  
329 but a different entity is involved in conducting the activity.
- 330 • “Requested” means that the public health authority has asked a different entity to conduct  
331 the activity, but the entity can decline to do so without consequence
- 332 • “Ordered” means that the public health authority has the legal authority to require the  
333 entity to conduct the activity.
- 334 • “Required” is synonymous with “ordered.”
- 335 • “Authorized by” means that that public health authority has given permission for the  
336 entity to conduct the activity.

337 SACHRP notes that “supported” and “requested” could potentially allow for more flexibility  
338 than the other terms. We believe that these terms should be interpreted narrowly.

339 **OHRP Question 5.** While this exclusion clearly may apply in the context of a public health  
340 emergency, it is not limited to the emergency context. What are the pros and cons involved in  
341 broad application of this exclusion? Please consider outlining such considerations from the  
342 perspective of a government agency acting as a public health authority, a non-governmental  
343 institution conducting a public health surveillance activity, and the individuals whose data and  
344 biospecimens will be used in the public health surveillance activity.

345 **SACHRP answer to Question 5**

346 A pro of allowing a broad application or interpretation of this exclusion is that it provides Public  
347 Health Authorities, both public and private, with more flexibility in the conduct of public health  
348 surveillance activities, and can reduce administrative burden and the need to consider whether  
349 informed consent is necessary. The con is that a broad application may harm public trust if it is  
350 applied to activities for which IRB review and consent would otherwise be required. The use of  
351 the exclusion should be transparent and used with a narrow application outside of a public health  
352 emergency. During a public health emergency, a broader application may be appropriate in  
353 order to allow Public Health Authorities to take appropriate and timely action to accomplish  
354 public health surveillance activities that are pressing and of wide concern.

355 **OHRP Question 6.** What entity or involved individual may or should decide whether a  
356 planned activity meets the requirements of this exclusion? Are there any recommended  
357 considerations involved with this decision, and do they differ depending on what entity or  
358 individual might be making this decision?

359 **SACHRP answer to Question 6**

360 SACHRP recommends that someone other than the principal investigator determine that the  
361 requirements for the exclusion are met, as is commonly instituted for consideration of the exempt  
362 categories in 45 CFR 46.104. Theoretically this could be an institutional duty, by an entity at  
363 an institution such as an IRB administrator, a research office, or an institutional official.  
364 However, public health surveillance activities often involve many institutions and may involve  
365 gathering information outside of institutional settings, so this may not be a practical approach. It  
366 will be more practical for an agency official to make the decision. However, such decisions  
367 should be clearly documented and readily available to the public to ensure transparency, and they  
368 should be narrowly applied. Also, transparency will be increased by providing the criteria or  
369 rationale for the decision, rather than just the final decision itself. SACHRP also recommends  
370 that institutions have a mechanism to review the decision and confirm agreement with the  
371 decision.

372 **OHRP Question 7.** Should documentation be recommended or required regarding each of the  
373 decision points involved with this exclusion? If so, please consider providing specific  
374 suggestions as to documentation and how entities or individuals should accomplish this.

375 **SACHRP answer to Question 7**

376 Yes. SACHRP believes that documentation of the decision that an activity is a public health  
377 surveillance activity should be documented with specific reference to how it meets 45 CFR  
378 46.102(l). This documentation should be publicly available, and easily accessible.

379 **OHRP Question 8.** This exclusion will not apply to activities dually regulated by FDA and  
380 OHRP. Are there any useful recommendations for involved institutions and individuals in such  
381 circumstances? (If not, feel free not to further consider this point.)

382 **SACHRP answer to Question 8**

383 SACHRP does not agree that it is universally true that “this exclusion will not apply to activities  
384 dually regulated by FDA and OHRP.” For instance, if a public health authority used HHS  
385 funding to conduct or support a surveillance program that involved return of COVID-19 test  
386 results to subjects, it seems that the project would meet the exclusion at 45 CFR 46.102(l)(2) and  
387 simultaneously require FDA review under 21 CFR 812 as an investigational diagnostic device.  
388

389 FDA does conduct some public health surveillance activities such as the Sentinel project, and as  
390 an HHS agency FDA can therefore utilize the exclusion for the public health surveillance  
391 activities that FDA conducts or supports. However, the FDA drug and device regulations do not  
392 include this exclusion at this time, and any clinical investigation of FDA regulated medical

393 products must follow those regulations, even if there are aspects of public health surveillance  
394 activities included in the project.

395 We note that CLIA is also not subject to the exclusion, and CLIA must be separately followed  
396 when it is applicable.

397 **SACHRP Commentary on OHRP draft guidance “Activities Deemed Not to Be Research:**  
398 **Public Health Surveillance 2018 Requirements”**

399 SACHRP has reviewed the OHRP draft guidance, and in general agrees with the draft guidance  
400 as written. SACHRP believes that several of the points bear repeating in this recommendation.

401 The draft guidance notes, “This explicit exclusion of public health surveillance activities from  
402 the definition of research does not mean that other public health activities that do not constitute  
403 public health surveillance activities, as described in 45 CFR 46.102(l)(2), are necessarily  
404 research subject to 45 CFR part 46.”

405  
406 Also, the draft guidance states, “Research activities that do not constitute public health  
407 surveillance, such as a secondary research analysis of data for some other scientific purpose  
408 using information collected as part of a public health surveillance activity, can be carried out in  
409 tandem with a public health surveillance activity. In such a circumstance, the non-public health  
410 surveillance activity (in the example above, the secondary research analysis) should be reviewed  
411 to determine whether the 2018 requirements apply.”  
412

413 **Algorithm:**

414 SACHRP has developed the following algorithm to help with the analysis of projects.

415 Is the project conducted, supported, requested, ordered, required, or authorized by a public health  
416 authority?

- 417     • If yes, proceed to question xxx  
418     • If no, it does not meet the exclusion

419 Does the project involve public health surveillance activities, including the collection and testing  
420 of information or biospecimens?

- 421     • If yes, proceed to question xx  
422     • If no, it does not meet the exclusion.

423 Does the project involve only public health surveillance activities?

- 424     • If yes, proceed to question xx  
425     • If no, the parts of the project that are not public health surveillance activities must be  
426         assessed separately to determine whether they are research, meet another exclusion, meet  
427         an exemption, or require IRB review.

428 Are the public health surveillance activities limited to those necessary to allow a public health  
429 authority to identify, monitor, assess, or investigate potential public health signals, onsets of

430 disease outbreaks, or conditions of public health importance (including trends, signals, risk  
431 factors, patterns in diseases, or increases in injuries from using consumer products)? Such  
432 activities include those associated with providing timely situational awareness and priority  
433 setting during the course of an event or crisis that threatens public health (including natural or  
434 man-made disasters).

435 The OHRP draft guidance “Activities Deemed Not to Be Research: Public Health Surveillance  
436 2018 Requirements” contains the following definitions of terms:

- 437 ✓ *Identify* generally refers to activities that are undertaken to detect potential  
438 signals, onsets of disease outbreaks, or conditions of public health  
439 importance that had not previously been recognized.
- 440 ✓ *Monitor* generally refers to activities that are undertaken to maintain  
441 situational awareness of an identified signal, outbreak, or condition, in  
442 order to detect changes that warrant further public health action.
- 443 ✓ *Assess* generally refers to activities that are undertaken to evaluate the  
444 characteristics of a signal, outbreak, or condition, including its magnitude,  
445 prevalence or incidence, and the context in which a signal, outbreak, or  
446 condition occurs or has been detected, in order to inform public health  
447 action.
- 448 ✓ *Investigate* generally refers to the range of activities that are undertaken in  
449 response to an identified or perceived threat to public health, to determine  
450 the magnitude of the problem, identify cases, or determine the cause, and  
451 to inform appropriate control measures. The problem under investigation  
452 might be a signal, an outbreak, or any other occurrence that warrants  
453 action.
- 454 ✓ *Provide situational awareness* refers to assembling the critical information  
455 that is needed to respond to a disease outbreak or other public health  
456 emergency.
- 457 ✓ *Potential public health signals, onsets of disease outbreaks, and*  
458 *conditions of public health importance* generally include conditions  
459 affecting health and safety, such as infectious and chronic diseases, injury,  
460 including those related to medical products, and mental health.

- 462 • If yes, the exclusion is met
- 463 • If no, it does not meet the exclusion.

464

465

466

467 **Parking Lot Notes** – Will not be in final version

468 A definition of public health surveillance activities will overlap with definition of research. If  
469 you have a Venn diagram of research and PHSA, and an activity falls within the overlap, then 1.

470 acceptable to use the exclusion or 2. this should be considered to be research? As a practical  
471 matter, we don't want an IRB looking at PHSA, so you should be able to separate them out.

472 Stephen – when in middle, consider it PHSA as narrowly defined. Not subject to common rule.  
473 Need to address temporal aspect, that collection, storage and use all need independent analysis of  
474 status as research or not.

475

476 Relevant OCR guidance on definition of PHA:

477 1) This is OCR's guidance from 2003 titled "DISCLOSURES FOR PUBLIC HEALTH ACTIVITIES"  
478 attached or found at [https://www.hhs.gov/hipaa/for-professionals/special-topics/public-](https://www.hhs.gov/hipaa/for-professionals/special-topics/public-health/index.html)  
479 [health/index.html](https://www.hhs.gov/hipaa/for-professionals/special-topics/public-health/index.html)

480

481 2) CDC published a report on HIPAA, where box #4 may provide a few specific examples  
482 <https://www.cdc.gov/mmwr/preview/mmwrhtml/m2e411a1.htm>

483

484 3) This might describe more specific example of how PHA is extended  
485 <https://www.cdc.gov/nhsn/hipaa/index.html>

486

487 4) Decision Tool to inform Disclosures for Emergency Preparedness - A Decision Tool: Is the  
488 Recipient a Public Health Authority (PHA)? It nicely lays out the definition of the PHA from  
489 HIPAA.

490

491 [https://www.hhs.gov/hipaa/for-professionals/special-topics/emergency-preparedness/is-](https://www.hhs.gov/hipaa/for-professionals/special-topics/emergency-preparedness/is-recipient-public-health-authority/index.html)  
492 [recipient-public-health-authority/index.html](https://www.hhs.gov/hipaa/for-professionals/special-topics/emergency-preparedness/is-recipient-public-health-authority/index.html)

493

494